Breaking — July 23, 2026
The FDA's Pharmacy Compounding Advisory Committee recommended all four Day 1 peptides for addition to the 503A Bulk Drug Substances List — overruling FDA scientists who opposed the move.
The committee reviewed four peptides on July 23. All four received a positive recommendation. The vote on each was 8 in favor, 6 against, 1 abstention.
BPC-157
Recommended ✓8 – 6 – 1
KPV
Recommended ✓8 – 6 – 1
TB-500
Recommended ✓8 – 6 – 1
MOTS-c
Recommended ✓8 – 6 – 1
DSIP
Jul 24 →Day 2
Semax
Jul 24 →Day 2
Epitalon
Jul 24 →Day 2
Important context: This is an advisory recommendation, not a final rule. The FDA is not legally bound by the committee's vote, though it follows committee recommendations in the vast majority of cases. Nothing changes for compounding access on July 23 — formal rulemaking must follow.
The FDA's Pharmacy Compounding Advisory Committee (PCAC) convened at FDA White Oak in Silver Spring, Maryland on July 23, 2026. The committee's job was to evaluate whether four peptides — BPC-157, KPV, TB-500, and MOTS-c — meet the criteria for inclusion on the 503A Bulk Drug Substances List under docket FDA-2025-N-6895.
FDA career scientists had published briefing documents recommending against adding any of the seven peptides, citing concerns about chemical characterization, inconsistent naming conventions, and insufficient human efficacy data. The committee disagreed.
Supporters of inclusion argued that the absence of disproving evidence was not equivalent to evidence of harm, and that access through licensed compounding pharmacies would actually improve quality control compared to the current grey market. The committee voted 8–6 with one abstention in favor of each peptide reviewed on Day 1.
BPC-157 and TB-500 are among the most widely researched and used compounded peptides in the United States. Both were removed from the FDA's Category 2 restricted list in April 2026 — a procedural step that teed them up for this review. Today's positive recommendation is the first time an FDA advisory body has formally supported a pathway toward legal compounded access for either compound.
KPV — a tripeptide fragment of alpha-MSH with studied applications in inflammatory bowel research — was also positively reviewed. KPV is one of the four components in KLOW, the quad-peptide stack.
Today's vote does not amend 21 CFR § 216.23. It does not authorize any compounding pharmacy to produce or dispense these peptides under 503A. The current status of these compounds — not on the approved bulks list — remains unchanged until the FDA completes formal rulemaking.
These peptides continue to be available for research purposes from suppliers that operate within applicable research-use frameworks.
Completed
Public Comment Period
Docket FDA-2025-N-6895 received approximately 1,860 public comments. Comment window closed July 22, 2026.
Completed — July 23–24, 2026
PCAC Vote
Advisory committee recommends for or against inclusion on the 503A Bulks List. All Day 1 peptides passed 8–6. Day 2 (DSIP, Semax, Epitalon) votes July 24.
Next — est. Q4 2026
FDA Considers Recommendation
FDA reviews the committee's recommendation alongside its own analysis. If FDA proceeds, it publishes a proposed rule.
est. Q4 2026 – Q1 2027
Proposed Rule & Second Comment Period
Public can comment on the proposed rule before it is finalized.
est. Q1 – Q2 2027
Final Rule Published
Only at this point would BPC-157, TB-500, KPV, and MOTS-c be formally added to the 503A Bulks List, enabling licensed compounding pharmacies to dispense them by individual prescription.
est. Before February 2027
Second PCAC Meeting
Five additional peptides — LL-37, GHK-Cu (injectable), Dihexa, Melanotan II, and PEG-MGF — go before the committee in a second meeting scheduled before the end of February 2027.
No. The PCAC vote is advisory. BPC-157 is not on the 503A Bulks List until the FDA completes rulemaking and publishes a final rule — a process estimated to take 6–18 months from a positive recommendation. Today's vote is a meaningful step, not the finish line.
Nothing changes immediately. Research peptides available through research suppliers continue to operate under the same frameworks as before the vote. The PCAC recommendation does not restrict or expand access to research-grade peptides.
The FDA is not legally bound by the committee's vote. However, the agency follows committee recommendations in the large majority of cases. If FDA proceeds with rulemaking, it will publish a proposed rule and accept additional public comment before finalizing.
Day 2 of the PCAC meeting is July 24, 2026. The committee will vote on DSIP (emideltide), Semax, and Epitalon on that date. Given the 8–6 pattern from Day 1, these peptides may follow the same trajectory.
Injectable GHK-Cu is on the agenda for the second PCAC meeting, scheduled before the end of February 2027. It was not included in the July 23–24 session.
The 503A Bulk Drug Substances List specifies which substances licensed compounding pharmacies (operating under Section 503A of the FD&C Act) may use to prepare compounded drugs against individual prescriptions. Inclusion does not constitute FDA approval or endorsement of a compound's safety or efficacy.
All products are pharmaceutical-grade research peptides, third-party tested by Janoshik Analytical with published COA results. For research use only.
View Research CatalogThis article is for informational and educational purposes only. All products sold by Evo Peptides are intended for in vitro research purposes only and are not for human or animal consumption. Nothing on this page constitutes legal, medical, or regulatory advice. Regulatory timelines cited are estimates based on publicly available FDA rulemaking history and may change. Always consult qualified legal and medical professionals for guidance on compounding regulations.